BofA goes long EUR/USD, sees Fed pivot as dollar headwind
BofA goes long EUR/USD, sees Fed pivot as dollar headwind
Source link
Similar Posts
Daily Broad Market Recap – October 16, 2025
The Thursday session was dominated by credit quality worries after two regional lenders disclosed problematic loans, triggering widespread risk aversion despite earlier optimism from strong bank earnings and continued AI investment momentum. Turns out investors aren’t fond of words like “fraud” and “charge-off” appearing in the same sentence as “regional bank.” Meanwhile, gold shrugged off…
Way of my EAs
Way of my EAs Source link
🎛️ The Need for Constant Action — Why Stillness Feels Uncomfortable
🎛️ The Need for Constant Action — Why Stillness Feels Uncomfortable 🎯 The Lesson Most traders don’t lose because they lack knowledge — they lose because they can’t sit still.Doing nothing feels wrong.Watching the chart without clicking feels like wasted time.So you enter trades just to “be active,” even when the market is saying “not…
Alphabet (GOOGL) Shares Drop Over 7% in a Single Day
According to the Alphabet (GOOGL) stock chart, yesterday’s main trading session opened around $163.70 but then saw a sharp decline, hitting an intraday low of approximately $148 per share. By the close, bulls managed to recover only a small portion of the losses. As a result, Alphabet (GOOGL) shares fell by more than 7% during…
Automating Your Trading Journey: How Trading Bots Help Beginners Achieve Consistent Results
Trading is an adventure filled with highs and lows, much like a journey through Middle-earth. But what if, like Frodo, you had a Samwise to guide you, keeping you grounded and ensuring you stay on course? A reliable trading bot can be that steadfast companion, taking you step-by-step toward more consistent results—without the unexpected detours….
Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA1 Data signal potential of novel, off-the-shelf approach in patients with extramedullary disease who face significant unmet needs1 BEERSE, BELGIUM, June 15, 2025 (GLOBE NEWSWIRE) — Janssen-Cilag International NV, a Johnson & Johnson…
